Details of the Drug

General Information of Drug (ID: DMY7PED)

Drug Name
Cisapride
Synonyms
cisapride; Propulsid; Prepulsid; Syspride; Pridesia; Risamal; Acenalin; Alimix; Propulsin; Propulsid Quicksolv; Enteropride; Kinestase; 81098-60-4; Cisawal; Vomiprid; Colinorm; Cisapron; Vomipride; Unipride; Kaudalit; Alipride; Acpulsif; Rapulid; Cipride; Pulsid; Esorid; Dispep; Presid; Unamol; Guptro; Alimix Forte; Cisapridum [Latin]; Cisaprida [Spanish]; R-51619; Cisapridum [INN-Latin]; R 51619; Cisaprida [INN-Spanish]; 104860-73-3; DCSUBABJRXZOMT-UHFFFAOYSA-N; T 1341; DSSTox_CID_2825; Acenalin; Cisaprida; Cisapridum; Risamol; Prepulsid (TN); Propulsid (TN); Cisapride (USAN/INN); Cisapride [USAN:BAN:INN:JAN]; Cis-4-Amino-5-chloro-N-(1-(3-(p-fluorophenoxy)propyl)-3-methoxy-4-piperidyl)-o-anisamide; (+-)-Cisapride; 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide; 4-amino-5-chloro-N-[1-{3-[(4-fluorophenyl)oxy]propyl}-3-(methyloxy)piperidin-4-yl]-2-(methyloxy)benzamide; 4-amino-5-chloro-N-{1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl}-2-methoxybenzamide; E-1454
Indication
Disease Entry ICD 11 Status REF
Gastroesophageal reflux disease DA22.Z Approved [1], [2]
Gastrointestinal disease DE2Z Investigative [3]
Therapeutic Class
Gastrointestinal Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 465.9
Topological Polar Surface Area (xlogp) 3.4
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 35-40% [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 1.5 mL/min/kg [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 6 - 12 hours [6]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.85434 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.02% [6]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.2 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0027 mg/mL [4]
Chemical Identifiers
Formula
C23H29ClFN3O4
IUPAC Name
4-amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide
Canonical SMILES
CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F
InChI
InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m1/s1
InChIKey
DCSUBABJRXZOMT-IRLDBZIGSA-N
Cross-matching ID
PubChem CID
6917698
ChEBI ID
CHEBI:3720
CAS Number
81098-60-4
DrugBank ID
DB00604
TTD ID
D0BD8D
VARIDT ID
DR00794
INTEDE ID
DR0331

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 4 receptor (HTR4) TT07C3Y 5HT4R_HUMAN Agonist [8], [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [11]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [12]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [11]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [12]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [12]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [12]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Gastroesophageal reflux disease
ICD Disease Classification DA22.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 4 receptor (HTR4) DTT HTR4 6.16E-01 -0.03 -0.24
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 5.57E-01 -7.89E-02 -7.93E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 4.32E-01 4.39E-02 4.30E-01
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 8.99E-01 4.59E-03 2.19E-02
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.57E-01 9.43E-03 1.29E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 9.62E-01 2.57E-02 1.10E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 2.35E-01 2.78E-02 2.09E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.76E-01 1.26E-01 8.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cisapride (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Cisapride and Ivosidenib. Acute myeloid leukaemia [2A60] [75]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Cisapride and Midostaurin. Acute myeloid leukaemia [2A60] [75]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Cisapride and Idarubicin. Acute myeloid leukaemia [2A60] [75]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Cisapride and Daunorubicin. Acute myeloid leukaemia [2A60] [75]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Cisapride and Arn-509. Acute myeloid leukaemia [2A60] [75]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Cisapride and Gilteritinib. Acute myeloid leukaemia [2A60] [75]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Cisapride and Oliceridine. Acute pain [MG31] [75]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Cisapride and Rivastigmine. Alzheimer disease [8A20] [75]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Cisapride and Donepezil. Alzheimer disease [8A20] [75]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Cisapride and Metronidazole. Amoebiasis [1A36] [76]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Cisapride and Ivabradine. Angina pectoris [BA40] [77]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Cisapride and Dronedarone. Angina pectoris [BA40] [75]
Nifedipine DMSVOZT Major Decreased metabolism of Cisapride caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [78]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Cisapride and Cilostazol. Arterial occlusive disease [BD40] [75]
Posaconazole DMUL5EW Major Decreased metabolism of Cisapride caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [78]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Cisapride and Levalbuterol. Asthma [CA23] [79]
Terbutaline DMD4381 Major Increased risk of ventricular arrhythmias by the combination of Cisapride and Terbutaline. Asthma [CA23] [80]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Cisapride and Pirbuterol. Asthma [CA23] [79]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Cisapride and Formoterol. Asthma [CA23] [80]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Cisapride and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [75]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Cisapride and Desipramine. Attention deficit hyperactivity disorder [6A05] [75]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Cisapride and Ofloxacin. Bacterial infection [1A00-1C4Z] [75]
Dalfopristin DM4LTKV Major Decreased metabolism of Cisapride caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [81]
Clarithromycin DM4M1SG Major Decreased metabolism of Cisapride caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [82]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Cisapride and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [75]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Cisapride and Gemifloxacin. Bacterial infection [1A00-1C4Z] [75]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Cisapride and Levofloxacin. Bacterial infection [1A00-1C4Z] [75]
Telithromycin DMZ4P3A Major Decreased metabolism of Cisapride caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [83]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Cisapride and Retigabine. Behcet disease [4A62] [75]
Erdafitinib DMI782S Moderate Increased metabolism of Cisapride caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [84]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Cisapride caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [85]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Cisapride and Loperamide. Bowel habit change [ME05] [86]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Cisapride and Eribulin. Breast cancer [2C60-2C6Y] [75]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Cisapride and Lapatinib. Breast cancer [2C60-2C6Y] [75]
Tucatinib DMBESUA Major Decreased metabolism of Cisapride caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [83]
Palbociclib DMD7L94 Moderate Decreased metabolism of Cisapride caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [78]
Tamoxifen DMLB0EZ Major Increased risk of prolong QT interval by the combination of Cisapride and Tamoxifen. Breast cancer [2C60-2C6Y] [75]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Cisapride and Bosutinib. Breast cancer [2C60-2C6Y] [75]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Cisapride and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [75]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Cisapride and Olodaterol. Chronic obstructive pulmonary disease [CA22] [80]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Cisapride and Vilanterol. Chronic obstructive pulmonary disease [CA22] [79]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Cisapride and Arformoterol. Chronic obstructive pulmonary disease [CA22] [80]
Isoproterenol DMK7MEY Major Increased risk of prolong QT interval by the combination of Cisapride and Isoproterenol. Conduction disorder [BC63] [80]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Cisapride and Halothane. Corneal disease [9A76-9A78] [75]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Cisapride and Propofol. Corneal disease [9A76-9A78] [87]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Cisapride and Sevoflurane. Corneal disease [9A76-9A78] [75]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Cisapride and Clofazimine. Crohn disease [DD70] [75]
Mifepristone DMGZQEF Major Decreased metabolism of Cisapride caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [88]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Cisapride and Pasireotide. Cushing syndrome [5A70] [75]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Cisapride and Osilodrostat. Cushing syndrome [5A70] [75]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Cisapride caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [89]
MK-8228 DMOB58Q Major Decreased metabolism of Cisapride caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [78]
Aprepitant DM053KT Major Decreased metabolism of Cisapride caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [90]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Cisapride and Sertraline. Depression [6A70-6A7Z] [75]
Nefazodone DM4ZS8M Major Decreased metabolism of Cisapride caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [88]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Cisapride and Escitalopram. Depression [6A70-6A7Z] [75]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Cisapride and Clomipramine. Depression [6A70-6A7Z] [75]
Trazodone DMK1GBJ Major Increased risk of prolong QT interval by the combination of Cisapride and Trazodone. Depression [6A70-6A7Z] [75]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Cisapride and Doxepin. Depression [6A70-6A7Z] [75]
Maprotiline DMPWB7T Major Increased risk of prolong QT interval by the combination of Cisapride and Maprotiline. Depression [6A70-6A7Z] [75]
Mepenzolate DM8YU2F Moderate Antagonize the effect of Cisapride when combined with Mepenzolate. Digestive system disease [DE2Z] [91]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Cisapride and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [75]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Cisapride and Deutetrabenazine. Dystonic disorder [8A02] [75]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Cisapride and Ingrezza. Dystonic disorder [8A02] [75]
Diazepam DM08E9O Moderate Altered absorption of Cisapride due to GI dynamics variation caused by Diazepam. Epilepsy/seizure [8A61-8A6Z] [92]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Cisapride caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [93]
Cenobamate DMGOVHA Moderate Increased metabolism of Cisapride caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [94]
Stiripentol DMMSDOY Major Decreased metabolism of Cisapride caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [78]
Ethacrynic acid DM60QMR Major Increased risk of ventricular arrhythmias by the combination of Cisapride and Ethacrynic acid. Essential hypertension [BA00] [91]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Cisapride and Solifenacin. Functional bladder disorder [GC50] [75]
Itraconazole DMCR1MV Major Decreased metabolism of Cisapride caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [78]
Pentamidine DMHZJCG Major Increased risk of prolong QT interval by the combination of Cisapride and Pentamidine. Fungal infection [1F29-1F2F] [75]
Miconazole DMPMYE8 Moderate Decreased metabolism of Cisapride caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [78]
Ketoconazole DMPZI3Q Major Decreased metabolism of Cisapride caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [78]
Propantheline DM2EN6G Moderate Antagonize the effect of Cisapride when combined with Propantheline. Gastric ulcer [DA60] [95]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Cisapride and Sunitinib. Gastrointestinal stromal tumour [2B5B] [75]
Acetazolamide DM1AF5U Major Increased risk of ventricular arrhythmias by the combination of Cisapride and Acetazolamide. Glaucoma [9C61] [95]
Methazolamide DM7J2TA Major Increased risk of ventricular arrhythmias by the combination of Cisapride and Methazolamide. Glaucoma [9C61] [95]
Dichlorphenamide DMH7IDQ Major Increased risk of ventricular arrhythmias by the combination of Cisapride and Dichlorphenamide. Glaucoma [9C61] [91]
Chlorothiazide DMLHESP Major Increased risk of ventricular arrhythmias by the combination of Cisapride and Chlorothiazide. Heart failure [BD10-BD1Z] [95]
Furosemide DMMQ8ZG Major Increased risk of ventricular arrhythmias by the combination of Cisapride and Furosemide. Heart failure [BD10-BD1Z] [95]
Bumetanide DMRV7H0 Major Increased risk of ventricular arrhythmias by the combination of Cisapride and Bumetanide. Heart failure [BD10-BD1Z] [95]
Hydroflumethiazide DMVPUQI Major Increased risk of ventricular arrhythmias by the combination of Cisapride and Hydroflumethiazide. Heart failure [BD10-BD1Z] [91]
Simeprevir DMLUA9D Major Decreased metabolism of Cisapride caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [78]
Rifapentine DMCHV4I Moderate Increased metabolism of Cisapride caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [96]
Delavirdine DM3NF5G Major Decreased metabolism of Cisapride caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Cisapride caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Cisapride and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [75]
Cobicistat DM6L4H2 Major Decreased metabolism of Cisapride caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Efavirenz DMC0GSJ Major Decreased metabolism of Cisapride caused by Efavirenz mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Saquinavir DMG814N Major Decreased metabolism of Cisapride caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Etravirine DMGV8QU Moderate Increased metabolism of Cisapride caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [97]
Amprenavir DMLMXE0 Major Decreased metabolism of Cisapride caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [91]
Darunavir DMN3GCH Major Decreased metabolism of Cisapride caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Atazanavir DMSYRBX Major Decreased metabolism of Cisapride caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Simvastatin DM30SGU Moderate Increased plasma concentrations of Cisapride and Simvastatin due to competitive inhibition of the same metabolic pathway. Hyper-lipoproteinaemia [5C80] [95]
Verapamil DMA7PEW Major Decreased metabolism of Cisapride caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [78]
Indapamide DMGN1PW Major Increased risk of ventricular arrhythmias by the combination of Cisapride and Indapamide. Hypertension [BA00-BA04] [95]
Hydrochlorothiazide DMUSZHD Major Increased risk of ventricular arrhythmias by the combination of Cisapride and Hydrochlorothiazide. Hypertension [BA00-BA04] [95]
Conivaptan DM1V329 Major Decreased metabolism of Cisapride caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [78]
Belladonna DM2RBWK Moderate Antagonize the effect of Cisapride when combined with Belladonna. Infectious gastroenteritis/colitis [1A40] [95]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Cisapride and Polyethylene glycol. Irritable bowel syndrome [DD91] [98]
Clidinium DMUMQZ0 Moderate Antagonize the effect of Cisapride when combined with Clidinium. Irritable bowel syndrome [DD91] [95]
Dicyclomine DMZSDGX Moderate Antagonize the effect of Cisapride when combined with Dicyclomine. Irritable bowel syndrome [DD91] [95]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Cisapride and Crizotinib. Lung cancer [2C25] [75]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Cisapride and Ceritinib. Lung cancer [2C25] [75]
PF-06463922 DMKM7EW Moderate Increased metabolism of Cisapride caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [99]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Cisapride and Osimertinib. Lung cancer [2C25] [75]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Cisapride and Selpercatinib. Lung cancer [2C25] [75]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Cisapride and Lumefantrine. Malaria [1F40-1F45] [75]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Cisapride and Chloroquine. Malaria [1F40-1F45] [75]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Cisapride and Hydroxychloroquine. Malaria [1F40-1F45] [75]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Cisapride and Primaquine. Malaria [1F40-1F45] [75]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Cisapride and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [75]
Idelalisib DM602WT Major Decreased metabolism of Cisapride caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [88]
IPI-145 DMWA24P Major Decreased metabolism of Cisapride caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [78]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Cisapride and Arsenic trioxide. Mature B-cell lymphoma [2A85] [100]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Cisapride and Vemurafenib. Melanoma [2C30] [75]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Cisapride caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [77]
Danazol DML8KTN Major Decreased metabolism of Cisapride caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [78]
Exjade DMHPRWG Moderate Decreased metabolism of Cisapride caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [101]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Cisapride and Panobinostat. Multiple myeloma [2A83] [75]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Cisapride and Thalidomide. Multiple myeloma [2A83] [76]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Cisapride and Fingolimod. Multiple sclerosis [8A40] [75]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Cisapride and Ozanimod. Multiple sclerosis [8A40] [75]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Cisapride and Romidepsin. Mycosis fungoides [2B01] [75]
Fedratinib DM4ZBK6 Major Decreased metabolism of Cisapride caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [78]
Imatinib DM7RJXL Major Decreased metabolism of Cisapride caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [78]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Cisapride and Dasatinib. Myeloproliferative neoplasm [2A20] [75]
Modafinil DMYILBE Moderate Increased metabolism of Cisapride caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [76]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Cisapride and Promethazine. Nausea/vomiting [MD90] [75]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Cisapride and Granisetron. Nausea/vomiting [MD90] [75]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Cisapride and Dolasetron. Nausea/vomiting [MD90] [75]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Cisapride and Ondansetron. Nausea/vomiting [MD90] [75]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Cisapride and Entrectinib. Non-small cell lung cancer [2C25] [75]
Polythiazide DMCH80F Major Increased risk of ventricular arrhythmias by the combination of Cisapride and Polythiazide. Oedema [MG29] [91]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Cisapride and Lofexidine. Opioid use disorder [6C43] [75]
Olaparib DM8QB1D Moderate Decreased metabolism of Cisapride caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [76]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Cisapride and Rucaparib. Ovarian cancer [2C73] [75]
Dextropropoxyphene DM23HCX Major Increased risk of prolong QT interval by the combination of Cisapride and Dextropropoxyphene. Pain [MG30-MG3Z] [75]
Buprenorphine DMPRI8G Major Increased risk of prolong QT interval by the combination of Cisapride and Buprenorphine. Pain [MG30-MG3Z] [75]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Cisapride and Triclabendazole. Parasitic worm infestation [1F90] [75]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Cisapride and Pimavanserin. Parkinsonism [8A00] [75]
Abametapir DM2RX0I Moderate Decreased metabolism of Cisapride caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [102]
Ranitidine DM0GUSX Minor Altered absorption of Cisapride due to GI dynamics variation caused by Ranitidine. Peptic ulcer [DA61] [103]
Methylscopolamine DM5VWOB Moderate Antagonize the effect of Cisapride when combined with Methylscopolamine. Peptic ulcer [DA61] [95]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Cisapride and Famotidine. Peptic ulcer [DA61] [76]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Cisapride and Macimorelin. Pituitary gland disorder [5A60-5A61] [104]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Cisapride and Lefamulin. Pneumonia [CA40] [75]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Cisapride caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [83]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Cisapride and Degarelix. Prostate cancer [2C82] [75]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Cisapride and ABIRATERONE. Prostate cancer [2C82] [75]
Nilutamide DMFN07X Major Increased risk of prolong QT interval by the combination of Cisapride and Nilutamide. Prostate cancer [2C82] [75]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Cisapride and Enzalutamide. Prostate cancer [2C82] [75]
Bicalutamide DMZMSPF Major Decreased metabolism of Cisapride caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [105]
Fluphenazine DMIT8LX Major Increased risk of prolong QT interval by the combination of Cisapride and Fluphenazine. Psychotic disorder [6A20-6A25] [75]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Cisapride and Gatifloxacin. Respiratory infection [CA07-CA4Z] [75]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Cisapride and Thioridazine. Schizophrenia [6A20] [75]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Cisapride and Aripiprazole. Schizophrenia [6A20] [76]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Cisapride and Iloperidone. Schizophrenia [6A20] [75]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Cisapride and Paliperidone. Schizophrenia [6A20] [75]
Perphenazine DMA4MRX Major Increased risk of prolong QT interval by the combination of Cisapride and Perphenazine. Schizophrenia [6A20] [75]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Cisapride and Trifluoperazine. Schizophrenia [6A20] [75]
Risperidone DMN6DXL Major Increased risk of prolong QT interval by the combination of Cisapride and Risperidone. Schizophrenia [6A20] [75]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Cisapride and Amisulpride. Schizophrenia [6A20] [75]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Cisapride and Asenapine. Schizophrenia [6A20] [75]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Cisapride and Pimozide. Schizophrenia [6A20] [75]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Cisapride and Vardenafil. Sexual dysfunction [HA00-HA01] [75]
Voxelotor DMCS6M5 Major Decreased metabolism of Cisapride caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [78]
Larotrectinib DM26CQR Moderate Decreased metabolism of Cisapride caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [76]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Cisapride and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [75]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Cisapride and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [75]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Cisapride and Pitolisant. Somnolence [MG42] [75]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Cisapride and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [75]
Adenosine DMM2NSK Major Increased risk of ventricular arrhythmias by the combination of Cisapride and Adenosine. Supraventricular tachyarrhythmia [BC81] [106]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Cisapride caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [107]
Brilinta DMBR01X Moderate Decreased metabolism of Cisapride caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [77]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Cisapride and Lenvatinib. Thyroid cancer [2D10] [75]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Cisapride and Cabozantinib. Thyroid cancer [2D10] [75]
Tizanidine DMR2IQ4 Major Increased risk of prolong QT interval by the combination of Cisapride and Tizanidine. Tonus and reflex abnormality [MB47] [75]
Sirolimus DMGW1ID Moderate Altered absorption of Cisapride due to GI dynamics variation caused by Sirolimus. Transplant rejection [NE84] [108]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Cisapride and Tacrolimus. Transplant rejection [NE84] [75]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Cisapride and Procainamide. Ventricular tachyarrhythmia [BC71] [75]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Cisapride and Propafenone. Ventricular tachyarrhythmia [BC71] [75]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Cisapride and Flecainide. Ventricular tachyarrhythmia [BC71] [75]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Cisapride and Amiodarone. Ventricular tachyarrhythmia [BC71] [75]
⏷ Show the Full List of 186 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 240).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020210.
3 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
4 BDDCS applied to over 900 drugs
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90.
9 The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):139-47.
10 Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther. 2003 Mar;73(3):209-22.
11 Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol. 2000 Apr;129(8):1655-67.
12 Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
13 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
23 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
24 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
25 Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
26 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
27 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
28 CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
29 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
30 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
31 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
32 Drug Interactions Flockhart Table
33 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
34 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
35 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
36 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
37 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
38 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
39 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
40 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
41 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
42 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
43 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
44 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
45 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
46 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
47 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
48 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
49 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
50 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
51 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
52 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
53 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
54 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
55 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
56 Drugs that may have potential CYP2B6 interactions.
57 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
58 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
59 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
60 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
61 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
62 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
63 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
64 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
65 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
66 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
67 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
68 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
69 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58.
70 The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37.
71 Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
72 The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
73 The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011 May 30;2:25.
74 A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015 Apr;13(4):701-8.e1.
75 Canadian Pharmacists Association.
76 Cerner Multum, Inc. "Australian Product Information.".
77 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
78 Bedford TA, Rowbotham DJ "Cisapride: drug interactions of clinical significance." Drug Saf 15 (1996): 167-75. [PMID: 8879971]
79 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
80 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
81 Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
82 Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
83 Desta Z, Soukhova N, Mahal SK, Flockhart DA "Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies." Drug Metab Dispos 28 (2000): 789-800. [PMID: 10859153]
84 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
85 Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
86 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
87 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
88 Bran S, Murray WA, Hirsch IB, Palmer JP "Long QT syndrome during high-dose cisapride." Arch Intern Med 155 (1995): 765-8. [PMID: 7695465]
89 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
90 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
91 Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57. [PMID: 10668858]
92 Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61. [PMID: 7882635]
93 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
94 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
95 Product Information. Propulsid (cisapride). Janssen Pharmaceutica, Titusville, NJ.
96 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
97 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
98 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
99 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
100 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
101 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
102 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
103 Rowbotham DJ, Milligan K, McHugh P "Effect of single doses of cisapride and ranitidine administered simultaneously on plasma concentrations of cisapride and ranitidine." Br J Anaesth 67 (1991): 302-5. [PMID: 1911017]
104 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
105 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
106 Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
107 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
108 Prescott WA Jr, Callahan BL, Park JM "Tacrolimus toxicity associated with concomitant metoclopramide therapy." Pharmacotherapy 24 (2004): 532-7. [PMID: 15098810]